Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy with interleukin 2, interferon α and 5-fluorouracil
E Herrmann, OA Brinkmann, ME Bode, S Bierer… - European urology, 2007 - Elsevier
E Herrmann, OA Brinkmann, ME Bode, S Bierer, T Köpke, M Bögemann, L Hertle, C Wülfing
European urology, 2007•ElsevierOBJECTIVES: Combined immunochemotherapy with interleukin 2 (IL-2), interferon α (IFN-
α), and 5-fluorouracil (5-FU) is an established first-line therapy for metastatic renal cell
carcinoma (RCC). However, data on histologic parameters predictive of clinical benefit are
rare. In this study, we evaluated the response to immunochemotherapy in the main
histologic subtypes of renal cell carcinoma and performed a subgroup analysis of
inoperable patients. METHODS: From 164 patients treated with one or two cycles of …
α), and 5-fluorouracil (5-FU) is an established first-line therapy for metastatic renal cell
carcinoma (RCC). However, data on histologic parameters predictive of clinical benefit are
rare. In this study, we evaluated the response to immunochemotherapy in the main
histologic subtypes of renal cell carcinoma and performed a subgroup analysis of
inoperable patients. METHODS: From 164 patients treated with one or two cycles of …
OBJECTIVES
Combined immunochemotherapy with interleukin 2 (IL-2), interferon α (IFN-α), and 5-fluorouracil (5-FU) is an established first-line therapy for metastatic renal cell carcinoma (RCC). However, data on histologic parameters predictive of clinical benefit are rare. In this study, we evaluated the response to immunochemotherapy in the main histologic subtypes of renal cell carcinoma and performed a subgroup analysis of inoperable patients.
METHODS
From 164 patients treated with one or two cycles of combined immunochemotherapy, radical nephrectomy had revealed 22 cases of papillary RCC (pRCC; 13.4%) and 131 cases of clear cell RCC (ccRCC; 79.9%). In the remaining 11 (6.7%) their disease was inoperable. The overall response rates were evaluated according to World Health Organization criteria.
RESULTS
For ccRCC and inoperable disease, responses of 34.4% and 27.3% after one cycle and 28.8% and 16.7% after two cycles, respectively, were noted. In contrast, no patient with pRCC showed any response after two cycles of combined immunochemotherapy.
CONCLUSIONS
No objective response was seen in patients with pRCC. Hence, the use of immunotherapeutic agents must be questioned in this histologic subtype.
Elsevier
